Pure Biologics to debut on WSE on December 14

Biotechnological company developing innovative biological drugs, Pure Biologics, will debut on the Regulated Market of the Warsaw Stock Exchange tomorrow. In recent weeks it has carried out an offer of shares worth PLN 54 million. After moving its quotations from the NewConnect market, the main intention of Pure Biologics in the coming year will be to continue work on the studied molecules, as well as to start the first experiments in the pre-clinical phase for three innovative projects.

“The transfer to the main floor of the Warsaw Stock Exchange is another important milestone in the company's operations. The successful public offering and the debut of the shares on the market are a consequence of the long-term development of the Company and an opportunity for its further dynamic growth. Joining the group of companies listed on the regulated market of the WSE will undoubtedly lend credence to our market position, also in the context of looking for business partners for a potential partnering agreement,” Dr. Filip Jeleń, co-founder and President of the Management Board of Pure Biologics, said.

As part of the Pure Biologics Public Offering, investors bought 600,000 series E shares. The issue price was set at PLN 90 per share. The company has been listed on the NewConnect market since December 2018. All series of the Company's shares previously listed on NewConnect and PDA of the new series E, which were subject to the public offering, will be introduced to trading. After the registration of the capital increase with the National Court Register, the Company will convert the Rights to Shares into series E shares.

(WBJ)